WEBVTT
Kind: captions
Language: en

00:00:12.650 --> 00:00:15.829 

tight<00:00:13.650> regulation<00:00:14.400> of<00:00:14.549> protein<00:00:15.030> synthesis<00:00:15.630> is

00:00:15.829 --> 00:00:15.839 
tight regulation of protein synthesis is

00:00:15.839 --> 00:00:18.519 
tight regulation of protein synthesis is
critical<00:00:16.440> to<00:00:16.619> normal<00:00:17.010> cellular<00:00:17.310> function

00:00:18.519 --> 00:00:18.529 
critical to normal cellular function

00:00:18.529 --> 00:00:21.679 
critical to normal cellular function
conversely<00:00:19.640> aberrant<00:00:20.640> protein<00:00:21.060> regulation

00:00:21.679 --> 00:00:21.689 
conversely aberrant protein regulation

00:00:21.689 --> 00:00:23.269 
conversely aberrant protein regulation
plays<00:00:22.109> an<00:00:22.289> important<00:00:22.769> role<00:00:22.830> in<00:00:23.189> the

00:00:23.269 --> 00:00:23.279 
plays an important role in the

00:00:23.279 --> 00:00:27.140 
plays an important role in the
pathogenesis<00:00:23.490> of<00:00:24.269> many<00:00:24.630> cancers<00:00:25.880> cells<00:00:26.880> have

00:00:27.140 --> 00:00:27.150 
pathogenesis of many cancers cells have

00:00:27.150 --> 00:00:29.480 
pathogenesis of many cancers cells have
evolved<00:00:27.539> intricate<00:00:28.109> signaling<00:00:28.619> pathways<00:00:29.160> for

00:00:29.480 --> 00:00:29.490 
evolved intricate signaling pathways for

00:00:29.490 --> 00:00:31.910 
evolved intricate signaling pathways for
regulating<00:00:30.090> protein<00:00:30.510> synthesis<00:00:31.080> recent

00:00:31.910 --> 00:00:31.920 
regulating protein synthesis recent

00:00:31.920 --> 00:00:33.950 
regulating protein synthesis recent
evidence<00:00:32.130> has<00:00:32.340> shown<00:00:32.489> that<00:00:32.759> mTOR<00:00:33.600> is<00:00:33.899> a

00:00:33.950 --> 00:00:33.960 
evidence has shown that mTOR is a

00:00:33.960 --> 00:00:36.590 
evidence has shown that mTOR is a
critical<00:00:34.649> signaling<00:00:35.190> protein<00:00:35.670> that<00:00:36.120> acts<00:00:36.360> as

00:00:36.590 --> 00:00:36.600 
critical signaling protein that acts as

00:00:36.600 --> 00:00:39.020 
critical signaling protein that acts as
a<00:00:36.660> master<00:00:37.200> regulator<00:00:37.530> of<00:00:37.800> protein<00:00:38.430> synthesis

00:00:39.020 --> 00:00:39.030 
a master regulator of protein synthesis

00:00:39.030 --> 00:00:41.810 
a master regulator of protein synthesis
mTOR<00:00:39.989> activity<00:00:40.530> is<00:00:40.739> controlled<00:00:41.280> by<00:00:41.430> a<00:00:41.460> number

00:00:41.810 --> 00:00:41.820 
mTOR activity is controlled by a number

00:00:41.820 --> 00:00:45.170 
mTOR activity is controlled by a number
of<00:00:42.059> upstream<00:00:42.540> signals<00:00:43.140> when<00:00:44.010> activated<00:00:44.640> the

00:00:45.170 --> 00:00:45.180 
of upstream signals when activated the

00:00:45.180 --> 00:00:47.540 
of upstream signals when activated the
mTOR<00:00:45.600> signal<00:00:46.079> has<00:00:46.230> a<00:00:46.260> powerful<00:00:46.680> downstream

00:00:47.540 --> 00:00:47.550 
mTOR signal has a powerful downstream

00:00:47.550 --> 00:00:50.569 
mTOR signal has a powerful downstream
effect<00:00:47.910> it<00:00:48.870> accelerates<00:00:49.620> the<00:00:49.860> synthesis<00:00:50.399> of

00:00:50.569 --> 00:00:50.579 
effect it accelerates the synthesis of

00:00:50.579 --> 00:00:52.760 
effect it accelerates the synthesis of
key<00:00:50.820> proteins<00:00:51.360> involved<00:00:51.719> in<00:00:52.260> critical

00:00:52.760 --> 00:00:52.770 
key proteins involved in critical

00:00:52.770 --> 00:00:55.869 
key proteins involved in critical
cellular<00:00:53.250> activities<00:00:53.840> growth<00:00:54.840> division

00:00:55.869 --> 00:00:55.879 
cellular activities growth division

00:00:55.879 --> 00:01:09.480 
cellular activities growth division
metabolism<00:00:56.879> and<00:00:57.090> angiogenesis

00:01:09.480 --> 00:01:09.490 

00:01:09.490 --> 00:01:12.399 

this<00:01:10.490> regulation<00:01:11.030> of<00:01:11.360> signals<00:01:11.780> upstream<00:01:12.380> of

00:01:12.399 --> 00:01:12.409 
this regulation of signals upstream of

00:01:12.409 --> 00:01:15.160 
this regulation of signals upstream of
mTOR<00:01:13.010> can<00:01:13.370> lead<00:01:13.580> to<00:01:13.790> pathological<00:01:14.540> increases

00:01:15.160 --> 00:01:15.170 
mTOR can lead to pathological increases

00:01:15.170 --> 00:01:18.730 
mTOR can lead to pathological increases
in<00:01:15.380> mTOR<00:01:15.770> signaling<00:01:16.150> for<00:01:17.150> example<00:01:17.740> mutations

00:01:18.730 --> 00:01:18.740 
in mTOR signaling for example mutations

00:01:18.740 --> 00:01:20.440 
in mTOR signaling for example mutations
of<00:01:18.890> a<00:01:19.010> tumor<00:01:19.369> suppressor<00:01:19.610> gene<00:01:20.210> or

00:01:20.440 --> 00:01:20.450 
of a tumor suppressor gene or

00:01:20.450 --> 00:01:22.530 
of a tumor suppressor gene or
amplification<00:01:21.140> of<00:01:21.560> two<00:01:21.800> proto<00:01:22.280> oncogenes

00:01:22.530 --> 00:01:22.540 
amplification of two proto oncogenes

00:01:22.540 --> 00:01:24.850 
amplification of two proto oncogenes
which<00:01:23.540> have<00:01:23.690> been<00:01:23.810> implicated<00:01:24.170> in<00:01:24.410> multiple

00:01:24.850 --> 00:01:24.860 
which have been implicated in multiple

00:01:24.860 --> 00:01:28.320 
which have been implicated in multiple
cancers<00:01:25.310> caused<00:01:26.060> over<00:01:26.509> activation<00:01:27.200> of<00:01:27.290> mTOR

00:01:28.320 --> 00:01:28.330 
cancers caused over activation of mTOR

00:01:28.330 --> 00:01:31.330 
cancers caused over activation of mTOR
let's<00:01:29.330> examine<00:01:29.690> in<00:01:29.900> detail<00:01:30.110> how<00:01:30.710> excessive

00:01:31.330 --> 00:01:31.340 
let's examine in detail how excessive

00:01:31.340 --> 00:01:33.430 
let's examine in detail how excessive
mTOR<00:01:31.850> signaling<00:01:31.909> leads<00:01:32.810> to<00:01:33.080> tumor

00:01:33.430 --> 00:01:33.440 
mTOR signaling leads to tumor

00:01:33.440 --> 00:01:35.890 
mTOR signaling leads to tumor
progression<00:01:33.650> by<00:01:34.610> increasing<00:01:35.240> the<00:01:35.360> synthesis

00:01:35.890 --> 00:01:35.900 
progression by increasing the synthesis

00:01:35.900 --> 00:01:49.010 
progression by increasing the synthesis
of<00:01:36.050> specific<00:01:36.710> intracellular<00:01:37.130> proteins

00:01:49.010 --> 00:01:49.020 

00:01:49.020 --> 00:01:51.530 

only<00:01:49.770> when<00:01:49.950> mTOR<00:01:50.369> is<00:01:50.579> activated<00:01:51.210> by<00:01:51.329> its

00:01:51.530 --> 00:01:51.540 
only when mTOR is activated by its

00:01:51.540 --> 00:01:53.569 
only when mTOR is activated by its
upstream<00:01:51.840> signals<00:01:52.530> does<00:01:52.950> it<00:01:53.070> become<00:01:53.340> capable

00:01:53.569 --> 00:01:53.579 
upstream signals does it become capable

00:01:53.579 --> 00:01:55.819 
upstream signals does it become capable
of<00:01:53.970> combining<00:01:54.390> with<00:01:54.689> specific<00:01:55.229> cytoplasmic

00:01:55.819 --> 00:01:55.829 
of combining with specific cytoplasmic

00:01:55.829 --> 00:01:58.690 
of combining with specific cytoplasmic
proteins<00:01:56.490> to<00:01:56.790> initiate<00:01:57.270> protein<00:01:57.750> synthesis

00:01:58.690 --> 00:01:58.700 
proteins to initiate protein synthesis

00:01:58.700 --> 00:02:02.270 
proteins to initiate protein synthesis
this<00:01:59.700> activated<00:02:00.270> mTOR<00:02:00.840> complex<00:02:01.439> induces

00:02:02.270 --> 00:02:02.280 
this activated mTOR complex induces

00:02:02.280 --> 00:02:04.789 
this activated mTOR complex induces
ribosomes<00:02:02.909> to<00:02:03.210> increase<00:02:03.600> translation<00:02:04.409> of<00:02:04.590> a

00:02:04.789 --> 00:02:04.799 
ribosomes to increase translation of a

00:02:04.799 --> 00:02:07.089 
ribosomes to increase translation of a
variety<00:02:04.979> of<00:02:05.340> proteins<00:02:05.850> which<00:02:06.390> drive<00:02:06.720> growth

00:02:07.089 --> 00:02:07.099 
variety of proteins which drive growth

00:02:07.099 --> 00:02:12.140 
variety of proteins which drive growth
division<00:02:08.239> metabolism<00:02:09.239> and<00:02:09.509> angiogenesis<00:02:11.150> the

00:02:12.140 --> 00:02:12.150 
division metabolism and angiogenesis the

00:02:12.150 --> 00:02:13.850 
division metabolism and angiogenesis the
production<00:02:12.630> of<00:02:12.720> one<00:02:12.959> particular<00:02:13.620> protein

00:02:13.850 --> 00:02:13.860 
production of one particular protein

00:02:13.860 --> 00:02:18.290 
production of one particular protein
cyclin<00:02:14.790> d<00:02:15.030> is<00:02:15.420> strongly<00:02:15.959> stimulated<00:02:17.300> over

00:02:18.290 --> 00:02:18.300 
cyclin d is strongly stimulated over

00:02:18.300 --> 00:02:20.750 
cyclin d is strongly stimulated over
expression<00:02:18.900> of<00:02:19.019> cyclin<00:02:19.470> d<00:02:19.650> sends<00:02:20.250> a<00:02:20.340> signal<00:02:20.550> to

00:02:20.750 --> 00:02:20.760 
expression of cyclin d sends a signal to

00:02:20.760 --> 00:02:23.420 
expression of cyclin d sends a signal to
the<00:02:20.910> nucleus<00:02:21.390> to<00:02:22.080> increase<00:02:22.470> transcription<00:02:23.310> of

00:02:23.420 --> 00:02:23.430 
the nucleus to increase transcription of

00:02:23.430 --> 00:02:26.030 
the nucleus to increase transcription of
specific<00:02:23.489> genes<00:02:24.269> which<00:02:24.750> speed<00:02:25.110> cell<00:02:25.560> cycle

00:02:26.030 --> 00:02:26.040 
specific genes which speed cell cycle

00:02:26.040 --> 00:02:29.479 
specific genes which speed cell cycle
progression<00:02:26.069> over<00:02:27.590> expression<00:02:28.590> of<00:02:28.830> cyclin<00:02:29.250> d

00:02:29.479 --> 00:02:29.489 
progression over expression of cyclin d

00:02:29.489 --> 00:02:42.459 
progression over expression of cyclin d
has<00:02:29.940> been<00:02:30.150> implicated<00:02:30.569> in<00:02:30.810> several<00:02:31.140> cancers

00:02:42.459 --> 00:02:42.469 

00:02:42.469 --> 00:02:45.530 

mTOR<00:02:43.469> overactivation<00:02:44.340> can<00:02:44.790> also<00:02:45.000> contribute

00:02:45.530 --> 00:02:45.540 
mTOR overactivation can also contribute

00:02:45.540 --> 00:02:48.860 
mTOR overactivation can also contribute
to<00:02:45.930> tumor<00:02:46.319> angiogenesis<00:02:47.209> under<00:02:48.209> hypoxic

00:02:48.860 --> 00:02:48.870 
to tumor angiogenesis under hypoxic

00:02:48.870 --> 00:02:51.470 
to tumor angiogenesis under hypoxic
conditions<00:02:49.430> activated<00:02:50.430> mTOR<00:02:50.849> signals

00:02:51.470 --> 00:02:51.480 
conditions activated mTOR signals

00:02:51.480 --> 00:02:53.690 
conditions activated mTOR signals
ribosomes<00:02:52.049> to<00:02:52.260> increase<00:02:52.799> production<00:02:53.219> of<00:02:53.579> the

00:02:53.690 --> 00:02:53.700 
ribosomes to increase production of the

00:02:53.700 --> 00:02:56.929 
ribosomes to increase production of the
intracellular<00:02:54.480> protein<00:02:54.930> f1<00:02:55.560> alpha<00:02:55.950> which

00:02:56.929 --> 00:02:56.939 
intracellular protein f1 alpha which

00:02:56.939 --> 00:02:59.360 
intracellular protein f1 alpha which
then<00:02:57.209> travels<00:02:57.689> to<00:02:57.750> the<00:02:57.959> nucleus<00:02:58.439> and<00:02:58.680> binds<00:02:59.159> to

00:02:59.360 --> 00:02:59.370 
then travels to the nucleus and binds to

00:02:59.370 --> 00:03:02.390 
then travels to the nucleus and binds to
its<00:02:59.609> partner<00:03:00.030> if<00:03:00.480> one<00:03:00.780> beta<00:03:01.049> the<00:03:01.829> resulting

00:03:02.390 --> 00:03:02.400 
its partner if one beta the resulting

00:03:02.400 --> 00:03:04.849 
its partner if one beta the resulting
hip<00:03:02.609> complex<00:03:03.180> stimulates<00:03:03.989> transcription<00:03:04.769> of

00:03:04.849 --> 00:03:04.859 
hip complex stimulates transcription of

00:03:04.859 --> 00:03:07.399 
hip complex stimulates transcription of
genes<00:03:04.920> coding<00:03:05.760> for<00:03:05.909> vascular<00:03:06.659> endothelial

00:03:07.399 --> 00:03:07.409 
genes coding for vascular endothelial

00:03:07.409 --> 00:03:10.819 
genes coding for vascular endothelial
growth<00:03:07.439> factor<00:03:08.099> or<00:03:08.280> veg<00:03:08.790> F<00:03:09.349> veg<00:03:10.349> F<00:03:10.590> is<00:03:10.799> a

00:03:10.819 --> 00:03:10.829 
growth factor or veg F veg F is a

00:03:10.829 --> 00:03:12.949 
growth factor or veg F veg F is a
cytokine<00:03:11.459> that<00:03:11.519> is<00:03:11.939> secreted<00:03:12.420> by<00:03:12.450> the<00:03:12.629> cell

00:03:12.949 --> 00:03:12.959 
cytokine that is secreted by the cell

00:03:12.959 --> 00:03:14.899 
cytokine that is secreted by the cell
and<00:03:13.230> promotes<00:03:13.799> the<00:03:14.040> formation<00:03:14.220> of<00:03:14.670> new<00:03:14.879> blood

00:03:14.899 --> 00:03:14.909 
and promotes the formation of new blood

00:03:14.909 --> 00:03:17.990 
and promotes the formation of new blood
vessels<00:03:15.569> that<00:03:15.780> feed<00:03:15.840> the<00:03:16.290> tumor<00:03:17.000> this

00:03:17.990 --> 00:03:18.000 
vessels that feed the tumor this

00:03:18.000 --> 00:03:20.300 
vessels that feed the tumor this
angiogenic<00:03:18.810> response<00:03:19.230> is<00:03:19.500> observed<00:03:19.859> in<00:03:20.069> many

00:03:20.300 --> 00:03:20.310 
angiogenic response is observed in many

00:03:20.310 --> 00:03:22.429 
angiogenic response is observed in many
tours<00:03:20.730> and<00:03:21.239> is<00:03:21.359> required<00:03:21.659> for<00:03:22.049> their<00:03:22.200> growth

00:03:22.429 --> 00:03:22.439 
tours and is required for their growth

00:03:22.439 --> 00:03:35.060 
tours and is required for their growth
and<00:03:22.680> metastasis

00:03:35.060 --> 00:03:35.070 

00:03:35.070 --> 00:03:37.410 

therapeutic<00:03:36.070> strategies<00:03:36.790> to<00:03:37.030> impair

00:03:37.410 --> 00:03:37.420 
therapeutic strategies to impair

00:03:37.420 --> 00:03:39.600 
therapeutic strategies to impair
signaling<00:03:38.020> through<00:03:38.290> the<00:03:38.410> mTOR<00:03:38.800> pathway<00:03:38.890> have

00:03:39.600 --> 00:03:39.610 
signaling through the mTOR pathway have

00:03:39.610 --> 00:03:40.970 
signaling through the mTOR pathway have
been<00:03:39.760> investigated

00:03:40.970 --> 00:03:40.980 
been investigated

00:03:40.980 --> 00:03:43.440 
been investigated
researchers<00:03:41.980> at<00:03:42.190> Aryan<00:03:42.670> pharmaceuticals

00:03:43.440 --> 00:03:43.450 
researchers at Aryan pharmaceuticals

00:03:43.450 --> 00:03:45.660 
researchers at Aryan pharmaceuticals
have<00:03:43.810> discovered<00:03:44.320> a<00:03:44.410> potent<00:03:44.860> selective

00:03:45.660 --> 00:03:45.670 
have discovered a potent selective

00:03:45.670 --> 00:03:48.510 
have discovered a potent selective
non-pro<00:03:46.570> drug<00:03:46.870> inhibitor<00:03:47.350> of<00:03:47.380> mTOR<00:03:47.860> known<00:03:48.340> as

00:03:48.510 --> 00:03:48.520 
non-pro drug inhibitor of mTOR known as

00:03:48.520 --> 00:03:52.080 
non-pro drug inhibitor of mTOR known as
a<00:03:48.700> p<00:03:49.030> two<00:03:49.390> three<00:03:49.690> five<00:03:49.960> seven<00:03:50.290> three<00:03:51.090> molecules

00:03:52.080 --> 00:03:52.090 
a p two three five seven three molecules

00:03:52.090 --> 00:03:54.750 
a p two three five seven three molecules
of<00:03:52.300> a<00:03:52.450> p<00:03:52.690> two<00:03:52.930> three<00:03:53.200> five<00:03:53.410> seven<00:03:53.710> three<00:03:54.010> passed

00:03:54.750 --> 00:03:54.760 
of a p two three five seven three passed

00:03:54.760 --> 00:03:56.880 
of a p two three five seven three passed
through<00:03:55.150> the<00:03:55.300> cell<00:03:55.510> membrane<00:03:55.540> and<00:03:56.200> form<00:03:56.830> a

00:03:56.880 --> 00:03:56.890 
through the cell membrane and form a

00:03:56.890 --> 00:03:58.860 
through the cell membrane and form a
complex<00:03:57.280> with<00:03:57.700> a<00:03:57.730> common<00:03:58.180> cytoplasmic

00:03:58.860 --> 00:03:58.870 
complex with a common cytoplasmic

00:03:58.870 --> 00:04:01.920 
complex with a common cytoplasmic
protein<00:03:59.500> this<00:04:00.220> complex<00:04:00.760> binds<00:04:01.180> tightly<00:04:01.540> to

00:04:01.920 --> 00:04:01.930 
protein this complex binds tightly to

00:04:01.930 --> 00:04:06.240 
protein this complex binds tightly to
mTOR<00:04:02.320> and<00:04:02.620> shuts<00:04:03.190> down<00:04:03.430> mTOR<00:04:04.000> signaling<00:04:05.250> as

00:04:06.240 --> 00:04:06.250 
mTOR and shuts down mTOR signaling as

00:04:06.250 --> 00:04:08.880 
mTOR and shuts down mTOR signaling as
anticipated<00:04:07.320> preclinical<00:04:08.320> studies<00:04:08.680> have

00:04:08.880 --> 00:04:08.890 
anticipated preclinical studies have

00:04:08.890 --> 00:04:10.980 
anticipated preclinical studies have
demonstrated<00:04:09.010> that<00:04:09.610> inhibition<00:04:10.420> of<00:04:10.540> mTOR

00:04:10.980 --> 00:04:10.990 
demonstrated that inhibition of mTOR

00:04:10.990 --> 00:04:14.070 
demonstrated that inhibition of mTOR
reduces<00:04:11.830> protein<00:04:12.280> synthesis<00:04:12.880> and<00:04:13.120> inhibits

00:04:14.070 --> 00:04:14.080 
reduces protein synthesis and inhibits

00:04:14.080 --> 00:04:17.280 
reduces protein synthesis and inhibits
cancer<00:04:14.620> cell<00:04:14.860> growth<00:04:15.210> division<00:04:16.290> metabolism

00:04:17.280 --> 00:04:17.290 
cancer cell growth division metabolism

00:04:17.290 --> 00:04:21.479 
cancer cell growth division metabolism
and<00:04:17.440> angiogenesis<00:04:19.560> ongoing<00:04:20.560> clinical<00:04:20.830> trials

00:04:21.479 --> 00:04:21.489 
and angiogenesis ongoing clinical trials

00:04:21.489 --> 00:04:25.470 
and angiogenesis ongoing clinical trials
are<00:04:21.700> underway<00:04:22.090> to<00:04:22.540> evaluate<00:04:23.470> a<00:04:23.740> p2<00:04:24.270> 3573

00:04:25.470 --> 00:04:25.480 
are underway to evaluate a p2 3573

00:04:25.480 --> 00:04:29.160 
are underway to evaluate a p2 3573
in<00:04:25.630> a<00:04:25.930> range<00:04:26.230> of<00:04:26.500> malignancies

